O'Kelly Michael, Li Siying
IQVIA, East Point Business Park, Dublin 3, Ireland.
IQVIA, Durham, NC.
Stat Biopharm Res. 2020 Oct 1;12(4):451-460. doi: 10.1080/19466315.2020.1811148.
Many clinical trials of treatments for patients hospitalised for COVID-19 use an ordinal scale recommended by the World Heath Organisation. The scale represents intensity of medical intervention, with higher scores for interventions more burdensome for the patient, and highest score for death. There is uncertainty about use of this ordinal scale in testing hypotheses. With the objective of assessing the power and Type I error of potential endpoints and analyses based on the ordinal scale, trajectories of the score over 28 days were simulated for scenarios based closely on results of two trials recently published. The simulation used transition probabilities for the ordinal scale over time. No one endpoint was optimal across scenarios, but a ranked measure of trajectory fared moderately well in all scenarios. Type I error was controlled at close to the nominal level for all endpoints. Because not tied to a particular population with regard to baseline severity, the use of transition probabilities allows plausible assessment of endpoints in populations with configurations of baseline score for which data is not yet published, provided some data on the relevant transition probabilities are available. The results could support experts in the choice of endpoint based on the ordinal scale.
许多针对因新冠肺炎住院患者的治疗临床试验采用了世界卫生组织推荐的序贯量表。该量表代表医疗干预的强度,分数越高表明干预措施对患者造成的负担越大,死亡的分数最高。在检验假设时使用这种序贯量表存在不确定性。为了评估基于序贯量表的潜在终点和分析的效能及I型错误,根据最近发表的两项试验结果,对密切相关的情景模拟了28天内分数的变化轨迹。模拟使用了序贯量表随时间的转移概率。在所有情景中,没有一个终点是最优的,但轨迹的排序测量在所有情景中表现中等。所有终点的I型错误都控制在接近名义水平。由于转移概率的使用不局限于特定基线严重程度的人群,因此只要有一些相关转移概率的数据,就可以对尚未公布基线分数配置人群的终点进行合理评估。研究结果可为专家基于序贯量表选择终点提供支持。